NAD+ and its derivatives NADH, NADP+, and NADPH are essential cofactors in redox reactions and electron transport pathways. NAD serves also as substrate for an extensive series of regulatory enzymes including cyclic ADP-ribose hydrolases, mono(ADP-ribosyl)transferases, poly(ADP-ribose) polymerases, and sirtuin deacetylases which are O-acetyl-ADP-ribosyltransferases. As a result of the numerous and diverse enzymes that utilize NAD as well as depend on its synthesis and concentration, significant interest has developed in its role in a variety of physiologic and pathologic processes, and therapeutic initiatives have focused both on augmenting its levels as well as inhibiting some of its pathways. In this article, we examine the biosynthesis of NAD, metabolic processes in which it is involved, and its role in aging, cancer, and other age-associated comorbidities including neurodegenerative, cardiovascular, and metabolic disorders. Therapeutic interventions to augment and/or inhibit these processes are also discussed.
Impact statement
NAD is a central metabolite connecting energy balance and organismal growth with genomic integrity and function. It is involved in the development of malignancy and has a regulatory role in the aging process. These processes are mediated by a diverse series of enzymes whose common focus is either NAD’s biosynthesis or its utilization as a redox cofactor or enzyme substrate. These enzymes include dehydrogenases, cyclic ADP-ribose hydrolases, mono(ADP-ribosyl)transferases, poly(ADP-ribose) polymerases, and sirtuin deacetylases. This article describes the manifold pathways that comprise NAD metabolism and promotes an increased awareness of how perturbations in these systems may be important in disease prevention and/or progression.
PollakNDölleCZieglerM.The power to reduce: pyridine nucleotides – small molecules with a multitude of functions. Biochem J2007;
402:205–18
2.
XiaoWWangRSHandyDELoscalzoJ.NAD(H) and NADP(H) redox couples and cellular energy metabolism. Antioxid Redox Signal2018;
28:251–72
3.
AgledalLNiereMZieglerM.The phosphate makes a difference: cellular functions of NADP. Redox Rep2010;
15:2–10
4.
LoveNRPollakNDölleaCNiereaMChenYOliveridPAmayaEPatelSZieglerM.NAD kinase controls animal NADP biosynthesis and is modulated via evolutionarily divergent calmodulin-dependent mechanisms. Proc Natl Acad Sci U S A2015;
112:1386–91
5.
GibsonBAKrausWL.New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol2012;
13:411–24
6.
SchreiberVDantzerFAméJCDe MurciaG.Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol2006;
7:517–28
7.
ImaiSIArmstrongCMKaeberleinMGuarenteL.Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature2000;
403:795–800
8.
ImaiSIGuarenteL.It takes two to tango: NAD+ and sirtuins in aging/longevity control. Aging Mech Dis2016;
2:1–6
9.
ElvehjemCAMaddenRJStrongFMWoolleyDW.The isolation and identification of the anti-black tongue factor. Nutr Rev1974;
32:48–50
10.
MorabiaA.Joseph goldberger's research on the prevention of pellagra. J R Soc Med2008;
101:566–8
11.
BonkowskiMSSinclairDA.Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds. Nat Rev Mol Cell Biol2016;
17:679–90
12.
DemarestTGBabbarMOkurMNDanXCroteauDLFakouriNBMattsonMPBohrVA.NAD+ metabolism in aging and cancer. Annu Rev Cancer Biol2019;
3:105–30
13.
GuarenteL.The resurgence of NAD+: restoring a mitochondrial metabolite slows stem cell loss and aging. Science2016;
352:1396–7
14.
ChowdhrySZancaCRajkumarUKogaTDiaoYRaviramRLiuFTurnerKYangHBrunkEBiJFurnariFBafnaVRenBMischelPS.NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling. Nature2019;
569:570–5
15.
YakuKOkabeKHikosakaKNakagawaT.NAD metabolism in cancer therapeutics. Front Oncol2018;
8:622
16.
ZhangHRyuDWuYGarianiKWangXLuanPD'AmicoDRopelleERLutolfMPAebersoldRSchoonjansKMenziesKJAuwerxJ.NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice. Science2016;
352:1436–43
17.
CurtinNJ.PARP inhibitors for cancer therapy. Expert Rev Mol Med2005;
7:1–20
18.
SalterMPogsonCI.The role of tryptophan 2,3-dioxygenase in the hormonal control of tryptophan metabolism in isolated rat liver cells: effects of glucocorticoids and experimental diabetes. Biochem J1985;
229:499–504
19.
YamazakiFKuroiwaTTakikawaOKidoR.Human indolylamine 2,3-dioxygenase. Its tissue distribution, and characterization of the placental enzyme. Biochem J1985;
230:635–8
20.
LiJVan ValkenburghJHongXContiPSZhangXChenK.Small molecules as theranostic agents in cancer immunology. Theranostics2019;
9:7849–71
21.
NguyenDJMTheodoropoulosGLiY-YWuCShaWFeunLGLampidisTJSavarajNWangpaichitrM.Targeting the kynurenine pathway for the treatment of cisplatin-resistant lung cancer. Mol Cancer Res2020;
18:105–17
22.
YeZYueLShiJShaoMWuT.Role of IDO and TDO in cancers and related diseases and the therapeutic implications. J Cancer2019;
10:2771–82
23.
ZahmCDJohnsonLEMcNeelDG.Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy. Cancer Immunol Immunother2019;
68:1661–9
24.
MagniGAmiciAEmanuelliMOrsomandoGRaffaelliNRuggieriS.Enzymology of NAD+ homeostasis in man. Cell Mol Life Sci2004;
61:19–34
25.
YounHSGyun KimTKimMKBu KangGYoun KangJLeeJGYop AnJRyoung ParkKLeeYJun ImYHyuck LeeJHyun EomS.Structural insights into the quaternary catalytic mechanism of hexameric human quinolinate phosphoribosyltransferase, a key enzyme in de novo NAD biosynthesis. Sci Rep2016;
6. doi: 10.1038/srep19681
26.
HorwittMKHarveyCCRothwellWSCutlerJLHaffronD.Tryptophan-Niacin relationships in man. J Nutrition1956;
60:1–43
27.
PreissJHandlerP.Biosynthesis of diphosphopyridine nucleotide. I. Identification of intermediates. J Biol Chem1958;
233:488–92
28.
PreissJHandlerP.Biosynthesis of diphosphopyridine nucleotide. II. Enzymatic aspects. J Biol Chem1958;
233:493–500
29.
GalassiLDi StefanoMBrunettiLOrsomandoGAmiciARuggieriSMagniG.Characterization of human nicotinate phosphoribosyltransferase: kinetic studies, structure prediction and functional analysis by site-directed mutagenesis. Biochimie2012;
94:300–9
30.
BalducciEEmanuelliMMagniGRaffaelliNRuggieriSVitaANataliniP.Nuclear matrix-associated NMN adenylyltransferase activity in human placenta. Biochem Biophys Res Commun1992;
189:1275–9
31.
BergerFLauCDahlmannMZieglerM.Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. J Biol Chem2005;
280:36334–41
32.
EmanuelliMCarnevaliFSaccucciFPierellaFAmiciARaffaelliNMagniG.Molecular cloning, chromosomal localization, tissue mRNA levels, bacterial expression, and enzymatic properties of human NMN adenylyltransferase. J Biol Chem2001;
276:406–12
33.
EmanuelliMNataliniPRaffaelliNRuggieriSVitaAMagniG.NAD biosynthesis in human placenta: purification and characterization of homogeneous NMN adenylyltransferase. Arch Biochem Biophys1992;
298:29–34
34.
RaffaelliNSorciLAmiciAEmanuelliMMazzolaFMagniG.Identification of a novel human nicotinamide mononucleotide adenylyltransferase. Biochem Biophys Res Commun2002;
297:835–40
35.
ZhangXKurnasovOVKarthikeyanSGrishinNVOstermanALZhangH.Structural characterization of a human cytosolic NMN/NaMN adenylyltransferase and implication in human NAD biosynthesis. J Biol Chem2003;
278:13503–11
36.
HaraNYamadaKTerashimaMOsagoHShimoyamaMTsuchiyaM.Molecular identification of human glutamine- and ammonia-dependent NAD synthetases: carbon-nitrogen hydrolase domain confers glutamine dependency. J Biol Chem2003;
278:10914–21
37.
BieganowskiPBrennerC.The reported human NADsyn2 is ammonia-dependent NAD synthetase from a pseudomonad. J Biol Chem2003;
278:33056–9
38.
HoutkooperRHCantóCWandersRJAuwerxJ.The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev2010;
31:194–223
39.
SvobodaPKrizovaESestakovaSVapenkovaKKnejzlikZRimpelovaSRayovaDVolfovaNKrizovaIRumlovaMSykoraDKizekRHaluzikMZidekVZidkovaJSkopV.Nuclear transport of nicotinamide phosphoribosyltransferase is cell cycle–dependent in mammalian cells, and its inhibition slows cell growth. J Biol Chem2019;
294:8676–89
40.
GardellSJHopfMKhanADispagnaMHampton SessionsEFalterRKapoorNBrooksJCulverJPetucciCMaC-TCohenSETanakaJBurgosESHirschiJSSmithSRSergienkoEPinkertonAB.Boosting NAD+ with a small molecule that activates NAMPT. Nat Commun2019;
10. doi: 10.1038/s41467-019-11078-z
41.
SunZLeiHZhangZ.Pre-B cell colony enhancing factor (PBEF), a cytokine with multiple physiological functions. Cytokine Growth Factor Rev2013;
24:433–42
42.
YoonMJYoshidaMJohnsonSTakikawaAUsuiITobeKNakagawaTYoshinoJ.Imai Si SIRT1-mediated eNAMPT secretion from adipose tissue regulates hypothalamic NAD+ and function in mice. Cell Metab2015;
21:706–17
43.
FriebeDNeefMKratzschJErbsSDittrichKGartenAPetzold-QuinqueSBlüherSReinehrTStumvollMBlüherMKiessWKörnerA.Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia2011;
54:1200–11
44.
KitaniTOkunoSFujisawaH.Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett2003;
544:74–8
45.
SamalBSunYStearnsGXieCSuggsSMcNieceI.Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol1994;
14:1431–7
46.
WangSNMiaoCY.Targeting NAMPT as a therapeutic strategy against stroke. Stroke Vasc Neurol2019;
4:83–9
47.
ZhangLQHeruthDPYeSQ.Nicotinamide phosphoribosyltransferase in human diseases. J Bioanal Biomed2011;
3:13–25
48.
BieganowskiPBrennerC.Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell2004;
117:495–502
49.
BoganKLBrennerC.Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD + precursor vitamins in human nutrition. Annu Rev Nutr2008;
28:115–30
50.
CantóCMenziesKJAuwerxJ.NAD+ metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab2015;
22:31–53
51.
LernerFNiereMLudwigAZieglerM.Structural and functional characterization of human NAD kinase. Biochem Biophys Res Commun2001;
288:69–74
52.
GroseJHJossLVelickSFRothJR.Evidence that feedback inhibition of NAD kinase controls responses to oxidative stress. Proc Natl Acad Sci U S A2006;
103:7601–6
53.
LiBBWangXTaiLMaTTShalmaniALiuWTLiWQChenKM.NAD kinases: metabolic targets controlling redox co-enzymes and reducing power partitioning in plant stress and development. Front Plant Sci2018;
9. doi: 10.3389/fpls.2018.00379
54.
OhashiKKawaiSMurataK.Identification and characterization of a human mitochondrial NAD kinase. Nat Commun2012;
3. doi: 10.1038/ncomms2262
55.
ZhangR.MNADK, a long-awaited human mitochondrion-localized NAD kinase. J Cell Physiol2015;
230:1697–701
56.
NakahataYBesshoY.The circadian NAD+ metabolism: impact on chromatin remodeling and aging. BioMed Res Int2016;
2016:3208429
57.
Van RoermundCWElgersmaYSinghNWandersRJTabakHF.The membrane of peroxisomes in Saccharomyces cerevisiae is impermeable to NAD(H) and acetyl-CoA under in vivo conditions. EMBO J1995;
14:3480–6
58.
RyuKWNanduTKimJChallaSDeBerardinisRJKrausWL.Metabolic regulation of transcription through compartmentalized NAD+ biosynthesis. Science2018;
360:eaan5780
NakagawaTLombDJHaigisMCGuarenteL.SIRT5 deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell2009;
137:560–70
61.
Van LindenMRDölleCPettersenIKNKulikovaVANiereMAgrimiGDyrstadSEPalmieriFNikiforovAATronstadKJZieglerM.Subcellular distribution of NAD+ between cytosol and mitochondria determines the metabolic profile of human cells. J Biol Chem2015;
290:27644–59
62.
YamadaKHaraNShibataTOsagoHTsuchiyaM.The simultaneous measurement of nicotinamide adenine dinucleotide and related compounds by liquid chromatography/electrospray ionization tandem mass spectrometry. Anal Biochem2006;
352:282–5
63.
DavilaALiuLChellappaKRedpathPNakamaru-OgisoEPaolellaLMZhangZMigaudMERabinowitzJDBaurJA.Nicotinamide adenine dinucleotide is transported into mammalian mitochondria. eLife2018;
7. doi: 10.7554/eLife.33246
64.
TrammellSAJSchmidtMSWeidemannBJRedpathPJakschFDellingerRWLiZAbelEDMigaudMEBrennerC.Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun2016;
7. doi: 10.1038/ncomms12948
65.
NikiforovADölleCNiereMZieglerM.Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation. J Biol Chem2011;
286:21767–78
66.
GrozioAMillsKFYoshinoJBruzzoneSSocialiGTokizaneKLeiHCCunninghamRSasakiYMigaudME.Imai Si Slc12a8 is a nicotinamide mononucleotide transporter. Nat Metab2019;
1:47–57
67.
DukesIDMcIntyreMSMertzRJPhilipsonLHRoeMWSpencerBWorleyJF3rdDependence on NADH produced during glycolysis for beta-cell glucose signaling. J Biol Chem1994;
269:10979–82
68.
LodishHBerkAZipurskySLMatsudairaPBaltimoreDDarnellJ.Electron transport and oxidative phosphorylation. Molecular Cell Biology. New York, NY: W. H. Freeman, 2000. p. 666-73
69.
GuoRGuJZongSWuMYangM.Structure and mechanism of mitochondrial electron transport chain. Biomed J2018;
41:9–20
70.
PirinenECantóCJoYSMoratoLZhangHMenziesKJWilliamsEGMouchiroudLMoullanNHagbergCLiWTimmersSImhofRVerbeekJPujolAVan LoonBViscomiCZevianiMSchrauwenPSauveAASchoonjansKAuwerxJ.Pharmacological inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle. Cell Metab2014;
19:1034–41
71.
WangY.Molecular links between caloric restriction and Sir2/SIRT1 activation. Diab Metab J2014;
38:321–9
72.
KellyDJHughesNJPooleRK.Microaerobic physiology: aerobic respiration, anaerobic respiration, and carbon dioxide metabolism. In: HLTMobleyGLMendzSLHazell (eds) Helicobacter pylori: physiology and genetics.
Washington, DC:
ASM Press, 2001, p. 113
73.
CroteauDLFangEFNilsenHBohrVA.NAD+ in DNA repair and mitochondrial maintenance. Cell Cycle2017;
16:491–2
74.
BergerNA.Poly(ADP-ribose) in the cellular response to DNA damage. Radiat Res1985;
101:4
75.
ZhangDHuXLiJLiuJBaks-Te BulteLWiersmaMMalik NuA van MarionDMSToloueeMHoogstra-BerendsFLantersEAHvan RoonAMde VriesAAFPijnappelsDAde GrootNMSHenningRHBrundelB.DNA damage-induced PARP1 activation confers cardiomyocyte dysfunction through NAD + depletion in experimental atrial fibrillation. Nat Commun2019;
10. doi: 10.1038/s41467-019-09014-2
BanasikMKomuraHShimoyamaMUedaK.Specific inhibitors of poly(ADP-ribose) synthetase and Mono(ADP-ribosyl)transferase. J Biol Chem1992;
267:1569–75
78.
GupteRLiuZKrausWL.PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. Genes Dev2017;
31:101–26
79.
OkazakiIJMossJ.Mono-ADP-ribosylation: a reversible posttranslational modification of proteins. Adv Pharmacol1996;
35:247–80
80.
LiuCYuX.ADP-ribosyltransferases and poly-ADP-ribosylation. Curr Protein Pept Sci2015;
16:491–501
81.
StevensLAKatoJKasamatsuAOdaHLeeD-YMossJ.The ARH and macrodomain families of α-ADP-ribose-acceptor hydrolases catalyze α-NAD+ hydrolysis. ACS Chem Biol2019;
14:2576–84
82.
YahiroKOguraKTerasakiYSatohMMiyagiSTerasakiMYamasakiEMossJ.Cholix toxin, an eukaryotic elongation factor 2 ADP-ribosyltransferase, interacts with prohibitins and induces apoptosis with mitochondrial dysfunction in human hepatocytes. Cell Microbiol2019;
21:e13033
83.
VaughanMMossJ.G proteins and toxin-catalyzed ADP-ribosylation. Biology of Cellular Transducing Signals. Boston, MA: Springer US, 1990. pp. 193-200
84.
WatanabeKKatoJZhuJOdaHIshiwata-EndoHMossJ.Enhanced sensitivity to cholera toxin in female ADP-ribosylarginine hydrolase (ARH1)-deficient mice. PLoS One2018;
13:e0207693
85.
FoleyBTMoehringJMMoehringTJ.Mutations In the elongation factor 2 gene which confer resistance to diphtheria toxin and pseudomonas exotoxin A: genetic and biochemical analyses. J Biol Chem1995;
270:23218–25
86.
LingFTangYLiMLiQ-SLiXYangLZhaoWJinC-CZengZLiuCWuC-FChenW-WLinXWangY-LThreadgillMD.Mono-ADP-ribosylation of histone 3 at arginine-117 promotes proliferation through its interaction with P300. Oncotarget2017;
8:72773–87
87.
ZolkiewskaA.Ecto-ADP-ribose transferases: cell-surface response to local tissue injury. Physiology2005;
20:374–81
88.
AdriouchSOhlroggeWHaagFKoch-NolteFSemanM.Rapid induction of naive T cell apoptosis by ecto-nicotinamide adenine dinucleotide: requirement for Mono(ADP-ribosyl)transferase 2 and a downstream effector. J Immunol2001;
167:196–203
89.
KawamuraHAswadFMinagawaMMaloneKKaslowHKoch-NolteFSchottWHLeiterEHDennertG.P2X7 receptor-dependent and -independent T cell death is induced by nicotinamide adenine dinucleotide. J Immunol2005;
174:1971–9
90.
BuXKatoJMossJ.Emerging roles of ADP-ribosyl-acceptor hydrolases (ARHs) in tumorigenesis and cell death pathways. Biochem Pharmacol2019;
167:44–9
91.
MashimoMMossJ.ADP-ribosyl-acceptor hydrolase activities catalyzed by the arh family of proteins. Methods Mol Biol2018;
1813:187–204
92.
MossJJacobsonMKStanleySJ.Reversibility of arginine-specific Mono(ADP-ribosyl)ation: identification in erythrocytes of an ADP-ribose-L-arginine cleavage enzyme. Proc Natl Acad Sci U S A1985;
82:5603–7
93.
MashimoMBuXAoyamaKKatoJIshiwata-EndoHStevensLAKasamatsuAWolfeLAToroCAdamsDMarkelloTGahlWAMossJ.PARP1 inhibition alleviates injury in ARH3-deficient mice and human cells. JCI Insight2019;
4:124519
94.
LeeHC.Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers. Annu Rev Pharmacol Toxicol2001;
41:317–45
95.
LeeHC.Cyclic ADP-ribose and nicotinic acid adenine dinucleotide phosphate (NAADP) as messengers for calcium mobilization. J Biol Chem2012;
287:31633–40
96.
MalavasiFDeaglioSFunaroAFerreroEHorensteinALOrtolanEVaisittiTAydinS.Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev2008;
88:841–86
97.
WeiWGraeffRYueJ.Roles and mechanisms of the CD38/cyclic adenosine diphosphate ribose/Ca(2+) signaling pathway. World J Biol Chem2014;
5:58–67
98.
QuaronaVZaccarelloGChillemiABrunettiESinghVKFerreroEFunaroAHorensteinALMalavasiF.CD38 and CD157: a long journey from activation markers to multifunctional molecules. Cytometry B Clin Cytom2013;
84:207–17
99.
ChiniCCSTarragóMGChiniEN.NAD and the aging process: role in life, death and everything in between. Mol Cell Endocrinol2017;
455:62–74
100.
AksoyPEscandeCWhiteTAThompsonMSoaresSBenechJCChiniEN.Regulation of SIRT1 mediated NAD dependent deacetylation: a novel role for the multifunctional enzyme CD38. Biochem Biophys Res Commun2006;
349:353–9
101.
Camacho-PereiraJTarragóMGChiniCCSNinVEscandeCWarnerGMPuranikASSchoonRAReidJMGalinaAChiniEN.CD38 dictates age-related NAD decline and mitochondrial dysfunction through a SIRT3-dependent mechanism. Cell Metab2016;
23:1127–39
102.
BarbosaMTPSoaresSMNovakCMSinclairDLevineJAAksoyPChiniEN.The enzyme CD38 (a NAD glycohydrolase, EC 3.2.2.5) is necessary for the development of diet-induced obesity. FASEB J2007;
21:3629–39
103.
WangL-FHuangC-CXiaoY-FGuanX-HWangX-NCaoQLiuYHuangXDengL-BDengK-YXinH-B.CD38 deficiency protects heart from high fat diet-induced oxidative stress via activating Sirt3/FOXO3 pathway. Cell Physiol Biochem2018;
48:2350–63
104.
GuanX-HLiuX-HHongXZhaoNXiaoY-FWangL-FTangLJiangKQianY-SDengK-YJiGFuMXinH-B.CD38 deficiency protects the heart from ischemia/reperfusion injury through activating SIRT1/FOXOs-mediated antioxidative stress pathway. Oxid Med Cell Longev2016;
2016:7410257
105.
HuYWangHWangQDengH.Overexpression of CD38 decreases cellular NAD levels and alters the expression of proteins involved in energy metabolism and antioxidant defense. J Proteome Res2014;
13:786–95
106.
BarataHThompsonMZielinskaWHanYSMantillaCBPrakashYSFeitozaSSieckGChiniEN.The role of cyclic-ADP-ribose-signaling pathway in oxytocin-induced Ca 2+ transients in human myometrium cells. Endocrinology2004;
145:881–9
107.
LeeCUSongEKYooCHKwakYKHanMK.Lipopolysaccharide induces CD38 expression and solubilization in J774 macrophage cells. Mol Cells2012;
34:573–6
108.
MussoTDeaglioSFrancoLCalossoLBadolatoRGarbarinoGDianzaniUMalavasiF.CD38 expression and functional activities are up-regulated by IFN-gamma on human monocytes and monocytic cell lines. J Leukoc Biol2001;
69:605–12
109.
GeYLongYXiaoSLiangLHeZYueCWeiXZhouY.CD38 affects the biological behavior and energy metabolism of nasopharyngeal carcinoma cells. Int J Oncol2019;
54:585–99
110.
JinDLiuHXHiraiHTorashimaTNagaiTLopatinaOShnayderNAYamadaKNodaMSeikeTFujitaKTakasawaSYokoyamaSKoizumiKShiraishiYTanakaSHashiiMYoshiharaTHigashidaKIslamMSYamadaNHayashiKNoguchiNKatoIOkamotoHMatsushimaASalminaAMunesueTShimizuNMochidaSAsanoMHigashidaH.CD38 is critical for social behaviour by regulating oxytocin secretion. Nature2007;
446:41–5
111.
LischkeTHeeschKSchumacherVSchneiderMHaagFKoch-NolteFMittrückerHW.CD38 controls the innate immune response against listeria monocytogenes. Infect Immun2013;
81:4091–9
112.
HassaPOHottigerMO.The diverse biological roles of mammalian PARPs, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci2008;
13:3046–82
113.
SodhiRKSinghNJaggiAS.Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications. Vascul Pharmacol2010;
53:77–87
114.
PleschkeJMKleczkowskaHEStrohmMAlthausFR.Poly(ADP-ribose) binds to specific domains in DNA damage checkpoint proteins. J Biol Chem2000;
275:40974–80
115.
CortesUTongW-MCoyleDLMeyer-FiccaMLMeyerRGPetrilliVHercegZJacobsonELJacobsonMKWangZ-Q.Depletion of the 110-kilodalton isoform of poly(ADP-ribose) glycohydrolase increases sensitivity to genotoxic and endotoxic stress in mice. Mol Cell Biol2004;
24:7163–78
116.
Ménissier De MurciaJNiedergangCTruccoCRicoulMDutrillauxBMarkMOliverFJMassonMDierichALemeurMWalztingerCChambonPDe MurciaG.Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A1997;
94:7303–7
117.
ShallSde MurciaG.Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?Mutat Res2000;
460:1–15
118.
BenekeSAlvarez-GonzalezRBürkleA.Comparative characterisation of poly(ADP-ribose) polymerase-1 from two mammalian species with different life span. Exp Gerontol2000;
35:989–1002
119.
GrubeKBurkleA.Poly(ADP-ribose) polymerase activity in mononuclear leukocytes of 13 mammalian species correlates with species-specific life span. Proc Natl Acad Sci U S A1992;
89:11759–63
120.
MuirasMLMüllerMSchächterFBürkleA.Increased poly(ADP-ribose) polymerase activity in lymphoblastoid cell lines from centenarians. J Mol Med1998;
76:346–54
121.
ChatterjeeSBergerSJBergerNA.Poly(ADP-ribose) polymerase: a guardian of the genome that facilitates DNA repair by protecting against DNA recombination. Mol Cell Biochem1999;
193:23–30
122.
BenekeSBürkleA.Poly(ADP-ribosyl)ation in mammalian ageing. Nucleic Acids Res2007;
35:7456–65
TongWMCortesUWangZQ.Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis. Biochim Biophys Acta2001;
1552:27–37
125.
RosadoMMBenniciENovelliFPioliC.Beyond DNA repair, the immunological role of PARP-1 and its siblings. Immunology2013;
139:428–37
126.
AgarwalAMahfouzRZSharmaRKSarkarOMangrolaDMathurPP.Potential Biological role of poly (ADP-ribose) polymerase (PARP) in male gametes. Reprod Biol Endocrinol2009;
7:143
127.
YamashitaSTanakaMNodonoHHamadaAHamadaTHasegawaMNishiYMossJMiwaM.Human alcohol dehydrogenase 1 is an acceptor protein for polyADP-ribosylation. Biochem Pharmacol2019;
167:27–32
128.
ColemanRLFlemingGFBradyMFSwisherEMSteffensenKDFriedlanderMOkamotoAMooreKNEfrat Ben-BaruchNWernerTLClovenNGOakninADiSilvestroPAMorganMANamJHLeathCANicumSHagemannARLittellRDCellaDBaron-HaySGarcia-DonasJMizunoMBell-McGuinnKSullivanDMBachBABhattacharyaSRatajczakCKAnsellPJDinhMHAghajanianCBookmanMA.Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med2019;
381:2403–15
129.
González-MartínAPothuriBVergoteIDePont ChristensenRGraybillWMirzaMRMcCormickCLorussoDHoskinsPFreyerGBaumannKJardonKRedondoAMooreRGVulstekeCO'CearbhaillRELundBBackesFBarretina-GinestaPHaggertyAFRubio-PérezMJShahinMSMangiliGBradleyWHBruchimISunKMalinowskaIALiYGuptaDMonkBJ.Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med2019;
381:2391–402
130.
RobsonMImS-ASenkusEXuBDomchekSMMasudaNDelalogeSLiWTungNArmstrongAWuWGoesslCRunswickSConteP.Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med2017;
377:523–33
131.
O'CearbhaillREGnjaticSAghajanianCIasonosAKonnerJALosadaNSarasohnDRasalanTTewWPZamarinDWongPSabbatiniP.A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission. J Clin Oncol2018;
36:5553
132.
GolanTHammelPReniMVan CutsemEMacarullaTHallMJParkJ-OHochhauserDArnoldDOhD-YReinacher-SchickATortoraGAlgülHO’ReillyEMMcGuinnessDCuiKYSchliengerKLockerGYKindlerHL.Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med2019;
381:317–27
133.
Virtanen Paunu Ahlskog Varnai Sipeky,
Sundvall PARP inhibitors in prostate cancer – the preclinical rationale and current clinical development. Genes2019;
10:565
134.
SachdevETabatabaiRRoyVRimelBJMitaMM.PARP inhibition in cancer: an update on clinical development. Target Oncol2019;
14:657–79
135.
KamT-IMaoXParkHChouS-CKaruppagounderSSUmanahGEYunSPBrahmachariSPanickerNChenRAndrabiSAQiCPoirierGGPletnikovaOTroncosoJCBekrisLMLeverenzJBPantelyatAKoHSRosenthalLSDawsonTMDawsonVL.Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson’s disease. Science2018;
362:eaat8407
136.
OlsenALFeanyMB.PARP inhibitors and Parkinson's disease. N Engl J Med2019;
380:492–94
137.
BergerNABessonVCBoularesAHBürkleAChiarugiAClarkRSCurtinNJCuzzocreaSDawsonTMDawsonVLHaskóGLiaudetLMoroniFPacherPRadermacherPSalzmanALSnyderSHSorianoFGStrosznajderRPSümegiBSwansonRASzaboC.Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. Br J Pharmacol2018;
175:192–222
138.
KimSCSprungRChenYXuYBallHPeiJChengTKhoYXiaoHXiaoLGrishinNVWhiteMYangXJZhaoY.Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell2006;
23:607–18
139.
PolevodaBShermanF.The diversity of acetylated proteins. Genome Biol2002;
3:reviews0006
140.
HillgartnerFBCharronTChesnutKA.Alterations in nutritional status regulate acetyl-CoA carboxylase expression in avian liver by a transcriptional mechanism. Biochem J1996;
319:263–68
141.
PietrocolaFGalluzziLBravo-San PedroJMMadeoFKroemerG.Acetyl coenzyme A: a central metabolite and second messenger. Cell Metab2015;
21:805–21
142.
RoyDPaulARoyAGhoshRGangulyPChaudhuriS.Differential acetylation of histone H3 at the regulatory region of OsDREB1b promoter facilitates chromatin remodelling and transcription activation during cold stress. PLoS One2014;
9:e100343
143.
YoshidaMShimazuTMatsuyamaA.Protein deacetylases: enzymes with functional diversity as novel therapeutic targets. Prog Cell Cycle Res2003;
5:269–78
144.
IvyJMKlarAJHicksJB.Cloning and characterization of four SIR genes of Saccharomyces cerevisiae. Mol Cell Biol1986;
6:688–702
145.
RineJHerskowitzI.Four genes responsible for a position effect on expression from HML and HMR in Saccharomyces cerevisiae. Genetics1987;
116:9–22
146.
BrachmannCBShermanJMDevineSECameronEEPillusLBoekeJD.The SIR2 gene family, conserved from bacteria to humans, functions in silencing, cell cycle progression, and chromosome stability. Genes Dev1995;
9:2888–902
147.
DerbyshireMKWeinstockKGStrathernJN.HST1, a new member of the SIR2 family of genes. Yeast1996;
12:631–40
148.
LeeCKKloppRGWeindruchRProllaTA.Gene expression profile of aging and its retardation by caloric restriction. Science1999;
285:1390–93
149.
LinSJDefossezPAGuarenteL.Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science2000;
289:2126–28
150.
LinSJFordEHaigisMLisztGGuarenteL.Calorie restriction extends yeast life span by lowering the level of NADH. Genes Dev2004;
18:12–16
151.
AndersonRMBittermanKJWoodJGMedvedikOSinclairDA.Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae. Nature2003;
423:181–5
152.
BelenkyPRacetteFGBoganKLMcClureJMSmithJSBrennerC.Nicotinamide riboside promotes Sir2 silencing and extends lifespan via NRK and Urh1/Pnp1/Meu1 pathways to NAD+. Cell2007;
129:473–84
153.
CostfordSRBajpeyiSPasaricaMAlbaradoDCThomasSCXieHChurchTSJubriasSAConleyKESmithSR.Skeletal muscle NAMPT is induced by exercise in humans. Am J Physiol2010;
298:E117–26
154.
FulcoMCenYZhaoPHoffmanEPMcBurneyMWSauveAASartorelliV.Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev Cell2008;
14:661–73
155.
WangRHZhaoTCuiKHuGChenQChenWWangXWSoto-GutierrezAZhaoKDengCX.Negative reciprocal regulation between Sirt1 and Per2 modulates the circadian clock and aging. Sci Rep2016;
6. doi: 10.1038/srep28633
156.
ChangH-CGuarenteL.SIRT1 mediates Central circadian control in the SCN by a mechanism that decays with aging. Cell2013;
153:1448–60
157.
MasriSRigorPCervantesMCegliaNSebastianCXiaoCRoqueta-RiveraMDengCOsborneTFMostoslavskyRBaldiPSassone-CorsiP.Partitioning circadian transcription by SIRT6 leads to segregated control of cellular metabolism. Cell2014;
158:659–72
158.
SunSLiuZFengYShiLCaoXCaiYLiuB.Sirt6 deacetylase activity regulates circadian rhythms via Per2. Biochem Biophys Res Commun2019;
511:234–38
SatohABraceCSRensingNCliftenPWozniakDFHerzogEDYamadaKAImaiSI.Sirt1 extends life span and delays aging in mice through the regulation of Nk2 homeobox 1 in the DMH and LH. Cell Metab2013;
18:416–30
161.
HerranzDMuñoz-MartinMCañameroMMuleroFMartinez-PastorBFernandez-CapetilloOSerranoM.Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun2010;
1. doi:10.1038/ncomms1001
162.
FurukawaATada-OikawaSKawanishiSOikawaS.H2O2 accelerates cellular senescence by accumulation of acetylated p53 via decrease in the function of SIRT1 by NAD depletion. Cell Physiol Biochem2007;
20:45–54
163.
GorenneIKumarSGrayKFiggNYuHMercerJBennettM.Vascular smooth muscle cell sirtuin 1 protects against DNA damage and inhibits atherosclerosis. Circulation2013;
127:386–96
164.
WilkingMJAhmadN.The role of SIRT1 in cancer: the Saga continues. Am J Pathol2015;
185:26–28
165.
DasCLuciaMSHansenKCTylerJK.CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature2009;
459:113–17
166.
NorthBJVerdinE.Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis. PLoS One2007;
2:e784
167.
AnwarTKhoslaSRamakrishnaG.Increased expression of SIRT2 is a novel marker of cellular senescence and is dependent on wild type p53 status. Cell Cycle2016;
15:1883–97
168.
JingEGestaSKahnCR.SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation. Cell Metab2007;
6:105–14
169.
WangFNguyenMQinFXFTongQ.SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell2007;
6:505–14
170.
SzabóAOláhJSzunyoghSLehotzkyASzénásiTCsaplárMSchiedelMLowPJungMOvádiJ.Modulation of microtubule acetylation by the interplay of TPPP/p25, SIRT2 and new anticancer agents with anti-SIRT2 potency. Sci Rep2017;
7. doi: 10.1038/s41598-017-17381-3
171.
KimHSVassilopoulosAWangRHLahusenTXiaoZXuXLiCVeenstraTDLiBYuHJiJWangXWParkSHChaYIGiusDDengCX.SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell2011;
20:487–99
172.
HiratsukaMInoueTTodaTKimuraNShirayoshiYKamitaniHWatanabeTOhamaETahimicCGTKurimasaAOshimuraM.Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun2003;
309:558–66
173.
LennerzVFathoMGentiliniCFryeRALifkeAFerelDWölfelCHuberCWölfelT.The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A2005;
102:16013–18
174.
DamodaranSDamaschkeNGawdzikJYangBShiCAllenGOHuangWDenuJJarrardD.Dysregulation of sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes. BMC Cancer2017;
17. doi: 10.1186/s12885-017-3853-9
175.
DanLKlimenkovaOKlimiankouMKlusmanJHvan den Heuvel-EibrinkMMReinhardtDWelteKSkokowaJ.The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. Haematologica2012;
97:551–9
176.
FunatoKHayashiTEchizenKNegishiLShimizuNKoyama-NasuRNasu-NishimuraYMorishitaYTabarVTodoTInoYMukasaASaitoNAkiyamaT.SIRT2-mediated inactivation of p73 is required for glioblastoma tumorigenicity. EMBO Rep2018;
19:e45587
177.
QuanSPrincipeDRDeanAEParkSHGrippoPJGiusDHorikoshiN.Loss of Sirt2 increases and prolongs a caerulein-induced pancreatitis permissive phenotype and induces spontaneous oncogenic Kras mutations in mice. Sci Rep2018;
8. doi: 10.1038/s41598-018-34792-y
178.
ZhouYWangQRychahouPWeissHLMark EversB.Differential role of SIRT2 protein in normal intestinal epithelium and colorectal cancer cells. Gastroenterology2017;
152:S252
179.
HuFSunXLiGWuQChenYYangXLuoXHuJWangG.Inhibition of SIRT2 limits tumour angiogenesis via inactivation of the STAT3/VEGFA signalling pathway. Cell Death Dis2018;
10:9
180.
GiraltAVillarroyaF.SIRT3, a pivotal actor in mitochondrial functions: metabolism, cell death and aging. Biochem J2012;
444:1–10
181.
SenguptaAHaldarD.Human sirtuin 3 (SIRT3) deacetylates histone H3 lysine 56 to promote nonhomologous end joining repair. DNA Repair2018;
61:1–16
182.
BauseASHaigisMC.SIRT3 regulation of mitochondrial oxidative stress. Exp Gerontol2013;
48:634–39
183.
LiuJLiDZhangTTongQYeRDLinL.SIRT3 protects hepatocytes from oxidative injury by enhancing ROS scavenging and mitochondrial integrity. Cell Death Dis2017;
8:e3158
184.
FinleyLWSCarracedoALeeJSouzaAEgiaAZhangJTeruya-FeldsteinJMoreiraPICardosoSMClishCBPandolfiPPHaigisMC.SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. Cancer Cell2011;
19:416–28
185.
BellELEmerlingBMRicoultSJHGuarenteL.SirT3 suppresses hypoxia inducible factor 1α and tumor growth by inhibiting mitochondrial ROS production. Oncogene2011;
30:2986–96
186.
KimHSPatelKMuldoon-JacobsKBishtKSAykin-BurnsNPenningtonJDvan der MeerRNguyenPSavageJOwensKMVassilopoulosAOzdenOParkSHSinghKKAbdulkadirSASpitzDRDengCXGiusD.SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell2010;
17:41–52
187.
XiaoKJiangJWangWCaoSZhuLZengHOuyangRZhouRChenP.Sirt3 is a tumor suppressor in lung adenocarcinoma cells. Oncol Rep2013;
30:1323–28
188.
YangHZhouLShiQZhaoYLinHZhangMZhaoSYangYLingZQGuanKLXiongYYeD.SIRT3‐dependent GOT2 acetylation status affects the malate–aspartate NADH shuttle activity and pancreatic tumor growth. EMBO J2015;
34:1110–25
189.
AlhazzaziTYKamarajanPJooNHuangJYVerdinED'SilvaNJKapilaYL.Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer2011;
117:1670–78
190.
AshrafNZinoSMacIntyreAKingsmoreDPayneAPGeorgeWDShielsPG.Altered sirtuin expression is associated with node-positive breast cancer. Br J Cancer2006;
95:1056–61
191.
GeorgeJNihalMSinghCKZhongWLiuXAhmadN.Pro-proliferative function of mitochondrial sirtuin deacetylase SIRT3 in human melanoma. J Invest Dermatol2016;
136:809–18
192.
MeiYChunsongYYuhuaP.Effects of downregulation of SIRT3 expression on proliferation and apoptosis in esophageal squamous cell carcinoma EC9706 cells and its molecular mechanisms. Bio med Mater Eng2014;
24:3883–90
193.
ShackelfordRHirshSHenryKAbdel-MageedAKandilECoppolaD.Nicotinamide phosphoribosyltransferase and SIRT3 expression are increased in well-differentiated thyroid carcinomas. Anticancer Res2013;
33:3047–52
194.
ChenYFuLLWenXWangXYLiuJChengYHuangJ.Sirtuin-3 (SIRT3), a therapeutic target with oncogenic and tumor-suppressive function in cancer. Cell Death Dis2014;
5:e1047
195.
ChoiYLTsukasakiKO'NeillMCYamadaYOnimaruYMatsumotoKOhashiJYamashitaYTsutsumiSKanedaRTakadaSAburataniHKamihiraSNakamuraTTomonagaMManoH.A genomic analysis of adult T-cell leukemia. Oncogene2007;
26:1245–55
196.
FuLDongQHeJWangXXingJWangEQiuXLiQ.SIRT4 inhibits malignancy progression of NSCLCs, through mitochondrial dynamics mediated by the ERK-Drp1 pathway. Oncogene2017;
36:2724–36
197.
JeongSMXiaoCFinleyLWSLahusenTSouzaALPierceKLiYHWangXLaurentGGermanNJXuXLiCWangRHLeeJCsibiACerioneRBlenisJClishCBKimmelmanADengCXHaigisMC.SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell2013;
23:450–63
198.
MiyoMYamamotoHKonnoMColvinHNishidaNKosekiJKawamotoKOgawaHHamabeAUemuraMNishimuraJHataTTakemasaIMizushimaTDokiYMoriMIshiiH.Tumour-suppressive function of SIRT4 in human colorectal cancer. Br J Cancer2015;
113:492–99
199.
SunHHuangDLiuGJianFZhuJZhangL.SIRT4 acts as a tumor suppressor in gastric cancer by inhibiting cell proliferation, migration, and invasion. Onco Targets Ther2018;
11:3959–68
200.
DuYHuHHuaCDuKWeiT.Tissue distribution, subcellular localization, and enzymatic activity analysis of human SIRT5 isoforms. Biochem Biophys Res Commun2018;
503:763–69
201.
DuJZhouYSuXYuJJKhanSJiangHKimJWooJKimJHChoiBHHeBChenWZhangSCerioneRAAuwerxJHaoQLinH.Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science2011;
334:806–09
202.
NishidaYRardinMJCarricoCHeWSahuAKGutPNajjarRFitchMHellersteinMGibsonBWVerdinE.SIRT5 regulates both cytosolic and mitochondrial protein malonylation with glycolysis as a major target. Mol Cell2015;
59:321–32
203.
LuWZuoYFengYZhangM.SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer. Tumour Biol2014;
35:10699–705
204.
SunXWangSGaiJGuanJLiJLiYZhaoJZhaoCFuLLiQ.SIRT5 promotes cisplatin resistance in ovarian cancer by suppressing dna damage in a ROS-dependent manner via regulation of the Nrf2/HO-1 pathway. Front Oncol2019;
9. doi: 10.3389/fonc.2019.00754
BartoschCMonteiro-ReisSAlmeida-RiosDVieiraRCastroAMoutinhoMRodriguesMGraçaILopesJMJerónimoC.Assessing sirtuin expression in endometrial carcinoma and nonneoplastic endometrium. Oncotarget2016;
7:1144–54
207.
LaiC-CLinP-MLinS-FHsuC-HLinH-CHuM-LHsuC-MYangM-Y.Altered expression of SIRT gene family in head and neck squamous cell carcinoma. Tumor Biol2013;
34:1847–54
208.
ArdestaniPMLiangF.Sub-cellular localization, expression and functions of Sirt6 during the cell cycle in HeLa cells. Nucleus2012;
3:442–51
209.
MichishitaEMcCordRABerberEKioiMPadilla-NashHDamianMCheungPKusumotoRKawaharaTLABarrettJCChangHYBohrVARiedTGozaniOChuaKF.SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature2008;
452:492–96
210.
MichishitaEMcCordRABoxerLDBarberMFHongTGozaniOChuaKF.Cell cycle-dependent deacetylation of telomeric histone H3 lysine K56 by human SIRT6. Cell Cycle2009;
8:2664–66
211.
Van MeterMMaoZGorbunovaVSeluanovA.SIRT6 overexpression induces massive apoptosis in cancer cells but not in normal cells. Cell Cycle2011;
10:3153–58
212.
MostoslavskyRChuaKFLombardDBPangWWFischerMRGellonLLiuPMostoslavskyGFrancoSMurphyMMMillsKDPatelPHsuJTHongALFordEChengHLKennedyCNunezNBronsonRFrendeweyDAuerbachWValenzuelaDKarowMHottigerMOHurstingSBarrettJCGuarenteLMulliganRDempleBYancopoulosGDAltFW.Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell2006;
124:315–29
213.
BaeJSParkSHJamiyandorjUKimKMNohSJKimJRParkHJKwonKSJungSHParkHSParkBHLeeHMoonWSSylvesterKGJangKY.CK2α/CSNK2A1 phosphorylates SIRT6 and is involved in the progression of breast carcinoma and predicts shorter survival of diagnosed patients. Am J Pathol2016;
186:3297–315
214.
KugelSSebastiánCFitamantJRossKNSahaSKJainEGladdenAAroraKSKatoYRiveraMNRamaswamySSadreyevRIGorenADeshpandeVBardeesyNMostoslavskyR.SIRT6 suppresses pancreatic cancer through control of Lin28b. Cell2016;
165:1401–15
215.
OuyangLYiLLiJYiSLiSLiuPYangX.SIRT6 overexpression induces apoptosis of nasopharyngeal carcinoma by inhibiting Nf-κB signaling. Onco Targets Ther2018;
11:7613–24
216.
TianJYuanL.Sirtuin 6 inhibits Colon cancer progression by modulating PTEN/AKT signaling. Biomed Pharmacother2018;
106:109–16
217.
ZhangCYuYHuangQTangK.SIRT6 regulates the proliferation and apoptosis of hepatocellular carcinoma via the ERK1/2 signaling pathway. Mol Med Rep2019;
20:1575–82
218.
BaeJSNohSJKimKMParkS-HHusseinUKParkHSParkB-HHaSHLeeHChungMJMoonWSChoDHJangKY.SIRT6 is involved in the progression of ovarian carcinomas via β-catenin-mediated epithelial to mesenchymal transition. Front Oncol2018;
8. doi: 10.3389/fonc.2018.00538
219.
Garcia-PetersonLMNdiayeMASinghCKChhabraGHuangWAhmadN.SIRT6 histone deacetylase functions as a potential oncogene in human melanoma. Genes Cancer2017;
8:701–12
220.
LiuYXieQRWangBShaoJZhangTLiuTHuangGXiaW.Inhibition of SIRT6 in prostate cancer reduces cell viability and increases sensitivity to chemotherapeutics. Protein Cell2013;
4:702–10
221.
OnnLPortilloMIlicSCleitmanGSteinDKaluskiSShiratISlobodnikZEinavMErdelFAkabayovBToiberD.SIRT6 is a DNA double-strand break sensor. eLife2020;
9:e51636
222.
TianXFirsanovDZhangZChengYLuoLTomblineGTanRSimonMHendersonSSteffanJGoldfarbATamJZhengKCornwellAJohnsonAYangJNMaoZMantaBDangWZhangZVijgJWolfeAMoodyKKennedyBKBohmannDGladyshevVNSeluanovAGorbunovaV.SIRT6 is responsible for more efficient DNA double-strand break repair in long-lived species. Cell2019;
177:622–38.e22
223.
ZhangWWanHFengGQuJWangJJingYRenRLiuZZhangLChenZWangSZhaoYWangZYuanYZhouQLiWLiuGHHuB.SIRT6 deficiency results in developmental retardation in cynomolgus monkeys. Nature2018;
560:661–65
224.
BarberMFMichishita-KioiEXiYTasselliLKioiMMoqtaderiZTennenRIParedesSYoungNLChenKStruhlKGarciaBAGozani1OLiWChuaKF.SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature2012;
487:114–18
225.
WuDLiYZhuKSWangHZhuW-G.Advances in cellular characterization of the sirtuin isoform, SIRT7. Front Endocrinol2018;
9. doi: 10.3389/fendo.2018.00652
226.
DengZWangXLongXLiuWXiangCBaoFWangD.Sirtuin 7 promotes colorectal carcinoma proliferation and invasion through the inhibition of E-cadherin. Exp Ther Med2018;
15:2333–42
227.
HuHZhuWQinJChenMGongLLiLLiuXTaoYYinHZhouHZhouLYeDYeQGaoD.Acetylation of PGK1 promotes liver cancer cell proliferation and tumorigenesis. Hepatology2017;
65:515–28
228.
WangH-LLuR-QXieS-HZhengHWenX-MGaoXGuoL.SIRT7 exhibits oncogenic potential in human ovarian cancer cells. Asian Pac J Cancer Prev2015;
16:3573–7
229.
ZhaoJWozniakAAdamsACoxJVittalAVossJBridgesBWeinmanSALiZ.SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway. J Exp Clin Cancer Res2019;
38:252
230.
HegyiJSchwartzRAHegyiV.Pellagra: dermatitis, dementia, and diarrhea. Int J Dermatol2004;
43:1–5
231.
ElvehjemCAMaddenRJStrongFMWolleyDW.The isolation and identification of the anti-black tongue factor. 1937. J Biol Chem2002;
277:e22
232.
KatsyubaEMottisAZietakMDe FrancoFvan der VelpenVGarianiKRyuDCialabriniLMatilainenOLiscioPGiacchèNStokar-RegenscheitNLegouisDde SeigneuxSIvanisevicJRaffaelliNSchoonjansKPellicciariRAuwerxJ.De novo NAD + synthesis enhances mitochondrial function and improves health. Nature2018;
563:354–59
233.
MaltosALPortariGVMoraesGVRodrigues MonteiroMCVannucchiHda CunhaDF.Niacin metabolism and indoleamine 2,3-dioxygenase activation in malnourished patients with flaky paint dermatosis. Nutrition2015;
31:890–92
234.
BraidyNGuilleminGJMansourHChan-LingTPoljakAGrantR.Age-related changes in NAD+ metabolism oxidative stress and SIRT1 activity in wistar rats. PLoS One2011;
6:e19194
235.
MassudiHGrantRBraidyNGuestJFarnsworthBGuilleminGJ.Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One2012;
7:e42357
236.
GomesAPPriceNLLingAJYMoslehiJJMontgomeryMKRajmanLWhiteJPTeodoroJSWrannCDHubbardBPMerckenEMPalmeiraCMDe CaboRRoloAPTurnerNBellELSinclairDA.Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell2013;
155:1624–38
237.
NacarelliTLauLFukumotoTZundellJFatkhutdinovNWuSAirdKMIwasakiOKossenkovAVSchultzDNoma Ki BaurJASchugZTangHYSpeicherDWDavidGZhangR.NAD+ metabolism governs the proinflammatory senescence-associated secretome. Nat Cell Biol2019;
21:397–407
238.
WileyCDCampisiJ.From ancient pathways to aging cells – connecting metabolism and cellular senescence. Cell Metab2016;
23:1013–21
239.
CoppéJ-PDesprezP-YKrtolicaACampisiJ.The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol2010;
5:99–118
240.
RizzaSFilomeniG.Regulation of S-nitrosylation in aging and senescence. Rejuvenation Res2019;
22:359–61
241.
LautrupSSinclairDAMattsonMPFangEF.NAD+ in brain aging and neurodegenerative disorders. Cell Metab2019;
30:630–55
242.
JohnsonSWozniakDFImaiS.CA1 Nampt knockdown recapitulates hippocampal cognitive phenotypes in old mice which nicotinamide mononucleotide improves. Aging Mech Dis2018;
4. doi: 10.1038/s41514-018-0029-z
LloretABealMF.PGC-1α, sirtuins and PARPs in Huntington’s disease and other neurodegenerative conditions: NAD+ to rule them all. Neurochem Res2019;
44:2423–34
247.
BlacherEBashiardesSShapiroHRothschildDMorUDori-BachashMKleimeyerCMoresiCHarnikYZurMZabariMBrikRBZKviatcovskyDZmoraNCohenYBarNLeviIAmarNMehlmanTBrandisABitonIKupermanYTsooryMAlfahelLHarmelinASchwartzMIsraelsonAArikeLJohanssonMEVHanssonGCGotkineMSegalEElinavE.Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature2019;
572:474–80
248.
DiguetNTrammellSAJTannousCDelouxRPiquereauJMougenotNGougeAGressetteMManouryBBlancJBretonMDecauxJFLaveryGGBaczkóIZollJGarnierALiZBrennerCMericskayM.Nicotinamide riboside preserves cardiac function in a mouse model of dilated cardiomyopathy. Circulation2018;
137:2256–73
249.
MatasicDSBrennerCLondonB.Emerging potential benefits of modulating NAD + metabolism in cardiovascular disease. Am J Physiol Heart Circ Physiol2018;
314:H839–H52
250.
WalkerMATianR.Raising NAD in heart failure: time to translate?Circulation2018;
137:2274–77
251.
KaneAESinclairDA.Sirtuins and NAD+ in the development and treatment of metabolic and cardiovascular diseases. Circ Res2018;
123:868–85
252.
LiuLWangPLiuXHeDLiangCYuY.Exogenous NAD+ supplementation protects H9c2 cardiac myoblasts against hypoxia/reoxygenation injury via Sirt1-p53 pathway. Fundam Clin Pharmacol2014;
28:180–89
253.
YamamotoTByunJZhaiPIkedaYOkaSSadoshimaJ.Nicotinamide mononucleotide, an intermediate of NAD+ synthesis, protects the heart from ischemia and reperfusion. PLoS One2014;
9:e98972
254.
ZhangYWangBFuXGuanSHanWZhangJGanQFangWYingWQuX.Exogenous NAD+ administration significantly protects against myocardial ischemia/reperfusion injury in rat model. Am J Transl Res2016;
8:3342–50
255.
PorterGAUrciuoliWRBrookesPSNadtochiySM.SIRT3 deficiency exacerbates ischemia-reperfusion injury: implication for aged hearts. Am J Physiol Heart Circ Physiol2014;
306:H1602–9
256.
MoynihanKAGrimmAAPluegerMMBernal-MizrachiEFordECras-MéneurCPermuttMAImaiSI.Increased dosage of mammalian Sir2 in pancreatic β cells enhances glucose-stimulated insulin secretion in mice. Cell Metab2005;
2:105–17
257.
BordoneLMottaMCPicardFRobinsonAJhalaUSApfeldJMcDonaghTLemieuxMMcBurneyMSzilvasiAEaslonEJLinS-JGuarenteL.Correction: Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic β cells. PLoS Biol2015;
13:e1002346
258.
BordoneLMottaMCPicardFRobinsonAJhalaUSApfeldJMcDonaghTLemieuxMMcBurneyMSzilvasiAEaslonEJLinSJGuarenteL.Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic β cells. PLoS Biol2006;
4:210–20
259.
ChenDBrunoJEaslonELinSJChengHLAltFWGuarenteL.Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev2008;
22:1753–57
260.
YingW.NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid Redox Signal2008;
10:179–206
